ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Feb 27, 2017
Recent Material Fair Value Estimate Changes
Fair value estimates are never static. Let's walk through some of the more material ones we've made during the past month or so.
Feb 27, 2017
Dividend Increases/Decreases for the Week Ending February 24
Let's take a look at companies raising/lowering their dividends this week.
Feb 24, 2017
Average Check Increases Driving Results for Cracker Barrel
Image Source: Mike Mozart. Dividend Growth Newsletter portfolio holding Cracker Barrel drove average check increases to combat weak traffic that continues to plague the restaurant space.
Feb 23, 2017
Is Clean Energy Just Burning Cash?
Image Source: Chuck Coker. Clean or renewable energy sources will undoubtedly be a part of how we generate power in the future, but how investible is the space? The answer is largely dependent on your risk tolerance.
Feb 23, 2017
PBMs: Express Scripts and CVS’ Looming Victory?
Image Source: Victor. We’re expecting a big win at CVS in coming years, and it may come at the expense of Express Scripts.
Feb 23, 2017
3 Critical Drug Approvals For Your Radar
Image Source: Neurocrine Biosciences.  What can investors expect when it comes to imminent drug approvals? Let’s cover three important ones.
Feb 20, 2017
Dividend Increases/Decreases for the Week Ending February 17
Let's take a look at companies raising/lowering their dividends this week.
Feb 18, 2017
Johnson & Johnson's Oncology Division A Force to Be Reckoned With
Image Source: Open Grid Scheduler. Healthcare and consumer staples giant Johnson & Johnson is a core holding in both newsletter portfolios. Let’s take a deep dive into one of its key sources of growth, its ‘Pharmaceutical’ segment.
Feb 17, 2017
Cisco Accelerating Recurring Revenue Base, Raises Dividend Double Digits
Image Source: Brandon Leon. Newsletter portfolio holding Cisco continues to transition its business to a software and subscription-based model. Let’s take a look its progress as of its second quarter of fiscal 2017.
Feb 15, 2017
Gilead Sciences Continues Its Meltdown
Image Source: Gilead. Valuentum has been out of Gilead in the newsletter portfolios for some time. As the Best Ideas Newsletter portfolio continues to make new highs, Gilead continues to set new 52-week lows. This is the power of “portfolio thinking,” something we've been preaching for a long time.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.